These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 8311448

  • 21. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 22. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
    Shrieve DC, Denekamp J, Minchinton AI.
    Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545
    [Abstract] [Full Text] [Related]

  • 23. Cyclophosphamide resistance in medulloblastoma.
    Friedman HS, Colvin OM, Kaufmann SH, Ludeman SM, Bullock N, Bigner DD, Griffith OW.
    Cancer Res; 1992 Oct 01; 52(19):5373-8. PubMed ID: 1356617
    [Abstract] [Full Text] [Related]

  • 24. Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
    Singh SV, Scalamogna D, Xia H, O'Toole S, Roy D, Emerson EO, Gupta V, Zaren HA.
    Int J Cancer; 1996 Mar 15; 65(6):852-7. PubMed ID: 8631603
    [Abstract] [Full Text] [Related]

  • 25. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
    Peters RH, Jollow DJ, Stuart RK.
    Cancer Res; 1991 May 15; 51(10):2536-41. PubMed ID: 2021933
    [Abstract] [Full Text] [Related]

  • 26. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells.
    Lutzky J, Astor MB, Taub RN, Baker MA, Bhalla K, Gervasoni JE, Rosado M, Stewart V, Krishna S, Hindenburg AA.
    Cancer Res; 1989 Aug 01; 49(15):4120-5. PubMed ID: 2568167
    [Abstract] [Full Text] [Related]

  • 27. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M, Broggini M.
    Cancer Res; 2002 Apr 15; 62(8):2332-6. PubMed ID: 11956092
    [Abstract] [Full Text] [Related]

  • 28. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
    Dusre L, Mimnaugh EG, Myers CE, Sinha BK.
    Cancer Res; 1989 Feb 01; 49(3):511-5. PubMed ID: 2535960
    [Abstract] [Full Text] [Related]

  • 29. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
    Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF.
    Cancer Res; 1984 Nov 01; 44(11):5427-31. PubMed ID: 6488194
    [Abstract] [Full Text] [Related]

  • 30. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells.
    Chen G, Waxman DJ.
    Biochem Pharmacol; 1995 May 26; 49(11):1691-701. PubMed ID: 7786310
    [Abstract] [Full Text] [Related]

  • 31. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
    Kang YJ.
    Cell Mol Biol Res; 1995 May 26; 41(2):131-6. PubMed ID: 8581064
    [Abstract] [Full Text] [Related]

  • 32. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C.
    Xu BH, Gupta V, Singh SV.
    Int J Cancer; 1994 Sep 01; 58(5):686-92. PubMed ID: 8077054
    [Abstract] [Full Text] [Related]

  • 33. Glutathione as a determinant of cellular response to doxorubicin.
    Lee FY, Vessey AR, Siemann DW.
    NCI Monogr; 1988 Sep 01; (6):211-5. PubMed ID: 3352767
    [Abstract] [Full Text] [Related]

  • 34. Glutathione related enzymes in cis-diamminedichloroplatinum (II)-sensitive and-resistant human ovarian carcinoma cells.
    Oguchi H, Kikkawa F, Kojima M, Maeda O, Mizuno K, Suganuma N, Kawai M, Tomoda Y.
    Anticancer Res; 1994 Sep 01; 14(1A):193-200. PubMed ID: 7909418
    [Abstract] [Full Text] [Related]

  • 35. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    Wu XX, Ogawa O, Kakehi Y.
    Int J Oncol; 2004 Jun 01; 24(6):1489-97. PubMed ID: 15138592
    [Abstract] [Full Text] [Related]

  • 36. Modulation of glutathione level in cultured human melanoma cells.
    Karg E, Brötell H, Rosengren E, Rorsman H.
    Acta Derm Venereol; 1989 Jun 01; 69(2):137-41. PubMed ID: 2564231
    [Abstract] [Full Text] [Related]

  • 37. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
    Chen G, Waxman DJ.
    Biochem Pharmacol; 1994 Mar 15; 47(6):1079-87. PubMed ID: 8147907
    [Abstract] [Full Text] [Related]

  • 38. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
    Bertsche U, Schorn H.
    Radiat Res; 1986 Mar 15; 105(3):351-69. PubMed ID: 3754339
    [Abstract] [Full Text] [Related]

  • 39. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
    Singh SV, Xu BH, Gupta V, Emerson EO, Zaren HA, Jani JP.
    Cancer Lett; 1995 Aug 16; 95(1-2):49-56. PubMed ID: 7656243
    [Abstract] [Full Text] [Related]

  • 40. 5-Fluorouracil cytotoxicity in human colon HT-29 cells with moderately increased or decreased cellular glutathione level.
    Chen MF, Chen LT, Boyce HW.
    Anticancer Res; 1995 Aug 16; 15(1):163-7. PubMed ID: 7733628
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.